Cargando…

New Strategies for Rehabilitation and Pharmacological Treatment of Fatigue Syndrome in Multiple Sclerosis

Multiple sclerosis (MS) is the most common autoimmune disease of the central nervous system (CNS), with an inflammatory demyelinating basis and a progressive course. The course of the disease is very diverse and unpredictable. Patients face many problems on a daily basis, such as problems with visio...

Descripción completa

Detalles Bibliográficos
Autores principales: Zielińska-Nowak, Ewa, Włodarczyk, Lidia, Kostka, Joanna, Miller, Elżbieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695014/
https://www.ncbi.nlm.nih.gov/pubmed/33171768
http://dx.doi.org/10.3390/jcm9113592
_version_ 1783615102984912896
author Zielińska-Nowak, Ewa
Włodarczyk, Lidia
Kostka, Joanna
Miller, Elżbieta
author_facet Zielińska-Nowak, Ewa
Włodarczyk, Lidia
Kostka, Joanna
Miller, Elżbieta
author_sort Zielińska-Nowak, Ewa
collection PubMed
description Multiple sclerosis (MS) is the most common autoimmune disease of the central nervous system (CNS), with an inflammatory demyelinating basis and a progressive course. The course of the disease is very diverse and unpredictable. Patients face many problems on a daily basis, such as problems with vision; sensory, balance, and gait disturbances; pain; muscle weakness; spasticity; tremor; urinary and fecal disorders; depression; and rapidly growing fatigue, which significantly influences quality of life among MS patients. Excessive fatigue occurs in most MS patients in all stages of this disease and is named MS-related fatigue. The crucial issue is the lack of effective treatment; therefore, this review focuses not only on the most common treatment methods, but also on additional novel therapies such as whole-body cryotherapy (WBC), functional electrical stimulation (FES), and non-invasive brain stimulation (NIBS). We also highlight the advantages and disadvantages of the most popular clinical scales used to measure fatigue. The entire understanding of the origins of MS-related fatigue may lead to the development of more effective strategies that can improve quality of life among MS patients. A literature search was performed using MEDLINE, EMBASE, and PEDro databases.
format Online
Article
Text
id pubmed-7695014
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76950142020-11-28 New Strategies for Rehabilitation and Pharmacological Treatment of Fatigue Syndrome in Multiple Sclerosis Zielińska-Nowak, Ewa Włodarczyk, Lidia Kostka, Joanna Miller, Elżbieta J Clin Med Review Multiple sclerosis (MS) is the most common autoimmune disease of the central nervous system (CNS), with an inflammatory demyelinating basis and a progressive course. The course of the disease is very diverse and unpredictable. Patients face many problems on a daily basis, such as problems with vision; sensory, balance, and gait disturbances; pain; muscle weakness; spasticity; tremor; urinary and fecal disorders; depression; and rapidly growing fatigue, which significantly influences quality of life among MS patients. Excessive fatigue occurs in most MS patients in all stages of this disease and is named MS-related fatigue. The crucial issue is the lack of effective treatment; therefore, this review focuses not only on the most common treatment methods, but also on additional novel therapies such as whole-body cryotherapy (WBC), functional electrical stimulation (FES), and non-invasive brain stimulation (NIBS). We also highlight the advantages and disadvantages of the most popular clinical scales used to measure fatigue. The entire understanding of the origins of MS-related fatigue may lead to the development of more effective strategies that can improve quality of life among MS patients. A literature search was performed using MEDLINE, EMBASE, and PEDro databases. MDPI 2020-11-07 /pmc/articles/PMC7695014/ /pubmed/33171768 http://dx.doi.org/10.3390/jcm9113592 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zielińska-Nowak, Ewa
Włodarczyk, Lidia
Kostka, Joanna
Miller, Elżbieta
New Strategies for Rehabilitation and Pharmacological Treatment of Fatigue Syndrome in Multiple Sclerosis
title New Strategies for Rehabilitation and Pharmacological Treatment of Fatigue Syndrome in Multiple Sclerosis
title_full New Strategies for Rehabilitation and Pharmacological Treatment of Fatigue Syndrome in Multiple Sclerosis
title_fullStr New Strategies for Rehabilitation and Pharmacological Treatment of Fatigue Syndrome in Multiple Sclerosis
title_full_unstemmed New Strategies for Rehabilitation and Pharmacological Treatment of Fatigue Syndrome in Multiple Sclerosis
title_short New Strategies for Rehabilitation and Pharmacological Treatment of Fatigue Syndrome in Multiple Sclerosis
title_sort new strategies for rehabilitation and pharmacological treatment of fatigue syndrome in multiple sclerosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695014/
https://www.ncbi.nlm.nih.gov/pubmed/33171768
http://dx.doi.org/10.3390/jcm9113592
work_keys_str_mv AT zielinskanowakewa newstrategiesforrehabilitationandpharmacologicaltreatmentoffatiguesyndromeinmultiplesclerosis
AT włodarczyklidia newstrategiesforrehabilitationandpharmacologicaltreatmentoffatiguesyndromeinmultiplesclerosis
AT kostkajoanna newstrategiesforrehabilitationandpharmacologicaltreatmentoffatiguesyndromeinmultiplesclerosis
AT millerelzbieta newstrategiesforrehabilitationandpharmacologicaltreatmentoffatiguesyndromeinmultiplesclerosis